Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Equity Income (2020 - 2025)

Beam Therapeutics (BEAM) has disclosed Equity Income for 6 consecutive years, with -$3.3 million as the latest value for Q4 2025.

  • Quarterly Equity Income fell 205.41% to -$3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2025, up 127.97% year-over-year, with the annual reading at $3.9 million for FY2025, 127.97% up from the prior year.
  • Equity Income for Q4 2025 was -$3.3 million at Beam Therapeutics, down from $4.9 million in the prior quarter.
  • The five-year high for Equity Income was $45.7 million in Q4 2022, with the low at -$25.5 million in Q3 2022.
  • Average Equity Income over 5 years is -$133050.0, with a median of -$2.7 million recorded in 2025.
  • The sharpest move saw Equity Income skyrocketed 4893.04% in 2021, then tumbled 839.65% in 2022.
  • Over 5 years, Equity Income stood at -$4.3 million in 2021, then surged by 1170.26% to $45.7 million in 2022, then tumbled by 101.58% to -$722000.0 in 2023, then plummeted by 50.97% to -$1.1 million in 2024, then tumbled by 205.41% to -$3.3 million in 2025.
  • According to Business Quant data, Equity Income over the past three periods came in at -$3.3 million, $4.9 million, and $4.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.